Avacta Group plc: Avacta Announces AffiDX SARS-CoV-2 Antigen Lateral Flow Test Receives CE Mark for Consumer Self-Testing
Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer and pre|CISION platforms, announces
Source: finanznachrichten.de